GLP1R and Alzheimer disease: The selective blockade of Aβ-induced activation of GLP-1R+ microglia by subcutaneous administration of NLY01 prevents reactive astrocytes conversion, neurodegeneration, and cognitive deficits without toxicity in animal models of AD [159].